Atlas Trials

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Clinical trial NCT04481763 · RECRUITING

Trial details

NCT number
NCT04481763
Sponsor
Jiangxi Provincial Cancer Hospital
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Triple-Negative Breast Cancer
Start date
2020-07-14
Primary completion
2024-08-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.